Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Categories
![test | Leukemia and Lymphoma Society [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2022/06/mp_66801_0_0jpg.jpg)
![I was battling Leukemia ( Blood+bone cancer), and God used me to bring healing to others Pt2 [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2022/06/mp_66840_0_0jpg.jpg)
![CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2022/06/mp_65782_0_0jpg.jpg)
![Approval of tisa-cel for follicular lymphoma [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2022/06/mp_65639_0_0jpg.jpg)